Pharma, Biotech and Generics Industry News | The Pharmaletter
6 days ago · Japanese mid-size drugmaker Otsuka Pharmaceutical announced that it has entered into an exclusive worldwide licensing agreement with Ionis Pharmaceuticals for rights to …
Pharmaceutical Industry News | The Pharmaletter
Nov 18, 2024 · Japanese mid-size drugmaker Otsuka Pharmaceutical announced that it has entered into an exclusive worldwide licensing agreement with Ionis Pharmaceuticals for rights …
Pharmaceutical Generics Industry News | The Pharmaletter
Sep 9, 2024 · Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets.
Login - The Pharmaletter
4 days ago · The Pharma Letter. 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom
FDA drug regulation and approval news | The Pharmaletter
4 days ago · Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug Administration (FDA) has issued a Complete Response …
About The Pharma Letter | The Pharmaletter
5 days ago · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered …
Pharma News and Insights Podcast | The Pharmaletter
Oct 10, 2023 · This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Pharma and Biotech Insights | The Pharmaletter
Nov 11, 2024 · Pharma and Biotech News Insights. As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely …
USA Clears Ivermectin For Human Use - The Pharma Letter
Dec 2, 1996 · In the USA, the Food and Drug Administration has approved Merck & Co's Stromectil (ivermectin) for its first non-veterinary use, the chemotherapy of two parasitic …
Pharma and Biotech News | The Pharmaletter
3 days ago · The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to 4.75 years from the time a drug receives approval …